Huaier Granule and Proteinuria

NCT07355361 · tracked via the Priya Life Science China tracker

Sponsor

Fudan University

Phase

Phase 2

Started

2026-01-15

Last updated

2026-01-21

Condition(s) studied

ProteinuriaBreast Cancer Patients

Investigational drug(s) / intervention(s)

Huaier GranuleAntitumor therapyProteinuria Management

Huaier Granule: Huaier Granule Group: Participants will take Huaier Granule (Z20000109) on top of their standard treatment. The dosing is 10g, orally, three times a day. Treatment continues until the study ends, or an event such as disease progression, unacceptable side effects, withdrawal, or death occurs, whichever comes first. The investigator can also stop treatment if it's no longer deemed beneficial. Refer to the drug label for details. The investigator will decide on continued use if the background cancer therapy is changed due to progression.

Antitumor therapy: The pre-existing regimen started before enrollment, subject to adjustment based on clinical routine.

Proteinuria Management: Specialist-managed care (including follow-up or drug therapy \[excluding Huaier Granule\]) initiated post-proteinuria diagnosis.

Study summary

The goal of this clinical trial is to learn if adding Huaier Granule to standard care can treat proteinuria (excess protein in the urine) in adult female breast cancer patients (aged 18-75) who developed this condition as a side effect of their immunotherapy or anti-angiogenic cancer treatment.

The main question it aims to answer is:

\* Does the addition of Huaier Granule to standard care improve the effectiveness of proteinuria treatment after 8 weeks?

Researchers will compare the group receiving standard care plus Huaier Granule to the group receiving standard care alone to see if the combination is more effective at reducing protein levels in the urine.

Participants will:

* Be randomly assigned to one of the two study groups.
* Continue their prescribed anti-cancer therapy (immunotherapy or anti-angiogenic therapy).
* Receive standard medical care for proteinuria from a kidney specialist.
* If in the experimental group, take Huaier Granule orally, three times a day.
* Attend clinic visits every 4 weeks for up to 24 weeks for check-ups and tests, including urine and blood tests.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * \*\*Inclusion Criteria\*\* 1. Female patients aged 18-75 years. 2. Histopathologically confirmed diagnosis of breast cancer. 3. Currently receiving or having a prior history of immunotherapy and/or anti-angiogenic therapy. 4. First-time detection of proteinuria on urinalysis, graded as +, ++, or +++. 5. 24-hour urinary protein quantification between 0.15g and 3.5g (exclusive). 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 7. Karnofsky Performance Status (KPS) score ≥70. 8. No prior treatment with Huaier Granule within one month before enrollment. 9. Life expectancy of at least 6 months. 10. Willingness to voluntarily participate in the study and provision of signed informed consent. Exclusion Criteria: * \*\*Exclusion Criteria\*\* 1. Known history of chronic kidney disease (eGFR \<60 ml/min/1.73m²) or diabetic nephropathy. 2. Proteinuria attributed to other diseases, including but not limited to primary renal disease, hypertension, urinary tract infection, systemic lupus erythematosus, or multiple myeloma. 3. Current use of ACEI/ARB medications (unless the dosage has been stable for ≥4 weeks prior to enrollment). 4. Known allergy, contraindication, or specific precaution to any component of Huaier Granule. 5. Women who are pregnant, breastfeeding, or planning to conceive. 6. Concurrent participation in any other clinical trial investigating medications for proteinuria. 7. Any other condition that, in the judgment of the investigator, would make the patient unsuitable for participation in this study.

Primary outcome measure(s)

Response rate of proteinuria treatment at Week 8 — From enrollment to the end of treatment at 8 weeks.
The proportion of subjects (across both groups) achieving a best overall response of Complete Response, Partial Response, or Stable Disease in proteinuria at 8 weeks.

Trial sites (1)

Facility	City	Region	Status
Fudan University Shanghai Cancer Center	Shanghai	Shanghai Municipality

More Fudan University trials in China

Real-World Study of Young Patients With Solid Tumors in China Recruiting

Preservation Vs. Dissection of No. 253 Lymph Nodes of Robotic Resection for Mid/Low Rectal Cancer Starting soon

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases Active, not recruiting

Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors Active, not recruiting

ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007) Recruiting

Other trials for the same condition

Nefecon and Ambrisentan in IgA Nephropathy Recruiting

Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study Recruiting

Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation Recruiting

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07355361 on ClinicalTrials.gov ↗ ← All trials in China